Bexotegrast (PLN-74809)是一种具有口服活性和强效性的 αvβ6和αvβ1 整合素抑制剂,具有抗纤维化作用,抑制 αvβ6 和αvβ1 诱导的 TGF-β 激活,可用于研究特发性肺纤维化(IPF)和非特异性间质性肺炎(NSIP)。 规格价格库存数量 1 mg¥ 993现货 ...
化学数据 CAS号2376257-44-0货号BCP49211 中文名Bexotegrast 英文名Bexotegrast 中文别名 英文别名PLN-74809;PLN 74809;PLN74809; 分子式C27H36N6O3分子量492.61 用途 生物活性Bexotegrast is a small-molecule that dually inhibits both αvβ6 and αvβ1 to treat both idiopathic pulmonary fibrosis (IPF...
基本信息 药品名称 PLN-74809; bexotegrast 药品类别 创新药; 化药; 小分子; potential first-in-class 靶点 αvβ6 integrin; αvβ1 integrin 作用机制 αvβ1抑制剂; αvβ6抑制剂 药品简介 -- 研发机构 Pliant Therapeutics 最高研发阶段 全球: II/III期临床 中国: 申报临床 审评审批类型...
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF) - PLN-74809-IPF-206 开始日期2024-08-08
Rationale: Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease that causes progressive cough, exertional dyspnea, impaired quality of life, and death. Objectives: Bexotegrast (PLN-74809) is an oral, once-daily, investigational drug in development for the ...
英文别名 HY-137561 | 2376257-44-0 | (S)-4-[(2-Methoxyethyl)[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(quinazolin-4-yl)amino]butanoic acid | BDBM50594476 | CS-0140405 | GLXC-26826 | Bexotegrast | PLN74809 | PLN-74809 | Butanoic acid, 4-[(2-methox ...
(Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company presented clinical data and preclinical data of bexotegrast (PLN-74809) this week as part of the ...
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and ...
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and ...